AI can identify hepatocellular carcinoma on liver CT exams
An artificial intelligence (AI) algorithm was able to identify hepatocellula...Read more on AuntMinnie.comRelated Reading:
Short ultrasound screening intervals improve liver cancer outcomes
Abbreviated MRI shows potential for HCC surveillance
Deep learning detects HCC on contrast-enhanced MRI
CE-MRI with CT extends life for patients with liver cancer
ISCT: Will AI for CT be radiology's killer app? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 10, 2021 Category: Radiology Source Type: news
Coffee protects against liver cancer while alcohol is linked with numerous cancers
Alcohol consumption is a major risk factor for several cancers including head & neck (mouth, pharynx, larynx), oesophageal and bowel cancer - as well as the more widely known links to breast and liver cancer - according to a new study funded by World Cancer Research Fund (WCRF)(1), and published this week in Nature Communications. The study also found increased coffee consumption was associated with a lower risk of developing liver cancer and basal cell carcinoma of the skin. (Source: World Pharma News)
Source: World Pharma News - August 4, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and effective ...
Source: Roche Investor Update - August 3, 2021 Category: Pharmaceuticals Source Type: news
US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and effective ...
Source: Roche Media News - August 3, 2021 Category: Pharmaceuticals Source Type: news
Study Supports Chemopreventive Effect of Statins on Liver Cancer in NASH Cirrhosis Study Supports Chemopreventive Effect of Statins on Liver Cancer in NASH Cirrhosis
New research provides supporting evidence for chemopreventive effects of statins on hepatocellular carcinoma in patients with nonalcoholic steatohepatitis cirrhosis.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 20, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
Hepatocellular Carcinoma, Novel Therapies on the Horizon Hepatocellular Carcinoma, Novel Therapies on the Horizon
Recent advancements have led to the identification and development of potential new treatment options for hepatocellular carcinoma.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Study sheds light on precise personalized hepatocellular carcinoma medicine
(Dalian Institute of Chemical Physics, Chinese Academy Sciences) Scientists identified hepatocellular carcinoma (HCC) subtypes with distinctive metabolic phenotypes through bioinformatics and machine learning methods, and elucidated the potential mechanisms based on a metabolite-protein interaction network and multi-omics data. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2021 Category: Cancer & Oncology Source Type: news
Tislelizumab Benefit in HCC Undimmed by Prior Therapies Tislelizumab Benefit in HCC Undimmed by Prior Therapies
Patients with advanced hepatocellular carcinoma (HCC) can achieve durable responses, and overall survival is"encouraging" with the novel immunotherapy, even after multiple prior therapies.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 6, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More Frequent Ultrasound Screening for People at High Risk for Liver Cancer May Be Worth It More Frequent Ultrasound Screening for People at High Risk for Liver Cancer May Be Worth It
Regular ultrasound screening with an interval between six and 12 months or less may lead to earlier detection of hepatocellular carcinoma in high-risk patients, according to a study from Taiwan.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 2, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
Oncotarget: Treatment outcomes in patients with advanced hepatocellular carcinoma
(Impact Journals LLC) In CTP class A patients, IGF/CTP score B was associated with shorter PFS and OS (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 28, 2021 Category: Cancer & Oncology Source Type: news
Genetic study of liver cancer reveals new drug target
(PLOS) Drugs targeting the gene MAGEA3 may help block the growth of hepatocellular carcinoma (HCC), the most common type of primary liver cancer and one of the leading causes of cancer deaths in the country. That's one conclusion of a new study analyzing the genetics of HCC tumors published June 24th in the journal PLOS Genetics by Augusto Villanueva of the Icahn School of Medicine at Mount Sinai and colleagues. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news
MD Anderson research highlights for June 16, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new combination therapy for acute myeloid leukemia (AML), a greater understanding of persistent conditions after AML remission, the discovery of a universal biomarker for exosomes, the identification of a tumor suppressor gene in hepatocellular carcinoma (HCC) and characterization of a new target to treat Clostridioides difficile (C. difficile) inf...
Source: EurekAlert! - Cancer - June 16, 2021 Category: Cancer & Oncology Source Type: news
Neoadjuvant and Adjuvant Treatment Approaches for HCC Neoadjuvant and Adjuvant Treatment Approaches for HCC
Learn more about the current neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma and the promising new options on the horizon.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Toward the first drug to treat a rare, lethal liver cancer
(Rockefeller University) After scouring more than 5,000 compounds, scientists have identified several new classes of therapeutics that may help treat fibrolamellar carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 14, 2021 Category: Cancer & Oncology Source Type: news
Oncotarget: The drug sensitivity of hepatocellular cancer cells
(Impact Journals LLC) 'Hepatocellular carcinoma (HCC) is the third leading cause of cancer related death worldwide, with a poor median survival time after diagnosis of six months.' (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 7, 2021 Category: Cancer & Oncology Source Type: news
